Halberd Corporation: Halberd Corp. Files Provisional Patent Application Complementing Patented Extracorporeal Radio Frequency/Laser Projects
JACKSON CENTER, PA / ACCESSWIRE / June 1, 2021 / Halberd Corporation (OTC PINK:HALB) announced the filing of a U. S. joint provisional patent application titled, Antibody Conjugated Nanoparticle Assay And Treatment For SARS-CoV-2. The innovation is a result of Halberd s Sponsored Research conducted at Arizona State University (ASU). The provisional patent application covers technology developed to facilitate conjugation of metallic nanoparticles with antibodies against various bacteria and SARS-CoV-2, for elimination via radio waves. Additionally, the patent discloses the use of such a conjugated moiety as a means of detecting the presence and level of the SARS-CoV-2 viral load in a patient.